Development of disease-specific pre-clinical PCS models
Our R&D team is researching methodologies to establish the following disease models for our future clients:
- Non-alcoholic fatty liver disease
- Alcoholic liver disease
- Paracetamol-induced liver toxicity
- Idiopathic pulmonary fibrosis
Development of new PCS organ platforms
Our R&D team is researching the design of PCS platforms for our future clients to determine the efficacy of their anti-fibrotic molecules in Human cardiac tissue.
Development of enhanced performance PCS
To ensure that our clients are provided with state-of-art technologies, our R&D team are continually researching and upgrading protocols for:
- optimisation of PCS preparation
- enhanced PCS culture conditions
- advancements to our PCS bioreactor hardware